Back to results
US 10,648,036 B2Granted
Receptor gene for peptide cancer antigen-specific T cell
AssigneeInternational Institute of Cancer Immunology, Inc.
InventorHaruo Sugiyama
Life of this patent
Estimating the term…
Abstract
The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.
Claims8
A method of assaying a clonality of WT1-specific cytotoxic T-cells (CTLs), the method comprising:
- (a) obtaining a sample from an HLA-A*0201-positive subject, wherein the sample is a tissue affected with a cancer which is generated from cells containing WT1, a body fluid, or a mucosal membrane;
- (b) sorting a single WT1-specific CTL in the sample;
- (c) amplifying a polynucleotide from the single WT1-specific CTL, the polynucleotide comprising:
- (i) a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1-756,
- (ii) a complementary RNA sequence of the nucleotide sequence (i), or
- (iii) a complementary DNA sequence of the nucleotide sequence (i);
- or
- hybridizing a polynucleotide in the single WT1-specific CTL with at least one polynucleotide comprising:
- (i) a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1-756,
- (ii) a complementary RNA sequence of the nucleotide sequence (i), or
- (iii) a complementary DNA sequence of the nucleotide sequence (i);
- and
- (d) measuring the clonality of WT1-specific CTLs that comprise an identical nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1-756, thereby characterizing the WT1-specific CTLs as having a multiplicity of clonality if the clonality is greater than 1,
- and/or
- measuring the number of types of WT1-specific CTLs having the multiplicity of clonality.
15 more elements
A method for assaying a clonality of WT1-specific CTLs, comprising:
- (a) obtaining a sample from an HLA-A*0201-positive subject, wherein the sample is a tissue affected with a cancer which is generated from cells containing WT1, a body fluid, or a mucosal membrane;
- (b) sorting a single WT1-specific CTL in the sample;
- (c) contacting a peptide from a single WT1-specific CTL with an antibody against a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 757-1512;
- and
- (d) measuring the clonality of WT1-specific CTLs that comprise an identical amino acid sequence selected from the group consisting of SEQ ID NOs:
- 757-1512, thereby characterizing the WT1-specific CTLs as having a multiplicity of clonality if the clonality is greater than 1;
- and/or
- measuring the number of types of WT1-specific CTLs that have a multiplicity of clonality.
6 more elements
Dependencies are inferred from the claim text.